Monoamine oxidase-B inhibition in Alzheimer's disease
Identifieur interne : 000E45 ( PascalFrancis/Corpus ); précédent : 000E44; suivant : 000E46Monoamine oxidase-B inhibition in Alzheimer's disease
Auteurs : Peter Riederer ; Walter Danielczyk ; Edna GrünblattSource :
- Neurotoxicology : (Park Forest South) [ 0161-813X ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 04-0191604 INIST |
---|---|
ET : | Monoamine oxidase-B inhibition in Alzheimer's disease |
AU : | RIEDERER (Peter); DANIELCZYK (Walter); GRÜNBLATT (Edna); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.) |
AF : | Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15/97080 Würzburg/Allemagne (1 aut., 3 aut.); Ludwig Boltzmann Institute of Clinical Neurobiology/Vienna/Autriche (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 271-277; Bibl. 2 p.1/2 |
LA : | Anglais |
EA : | Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD. |
CC : | 002A25; 002B03; 002B17 |
FD : | Amine oxidase (flavin-containing); Inhibition; Inhibiteur; Démence Alzheimer; Neurologie; Toxicologie |
FG : | Oxidoreductases; Enzyme; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie |
ED : | Amine oxidase (flavin-containing); Inhibition; Inhibitor; Alzheimer disease; Neurology; Toxicology |
EG : | Oxidoreductases; Enzyme; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases |
SD : | Amine oxidase (flavin-containing); Inhibición; Inhibidor; Demencia Alzheimer; Neurología; Toxicología |
LO : | INIST-18397.354000119285470280 |
ID : | 04-0191604 |
Links to Exploration step
Pascal:04-0191604Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Monoamine oxidase-B inhibition in Alzheimer's disease</title>
<author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name>
<affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1>
<s2>97080 Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Danielczyk, Walter" sort="Danielczyk, Walter" uniqKey="Danielczyk W" first="Walter" last="Danielczyk">Walter Danielczyk</name>
<affiliation><inist:fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grunblatt, Edna" sort="Grunblatt, Edna" uniqKey="Grunblatt E" first="Edna" last="Grünblatt">Edna Grünblatt</name>
<affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1>
<s2>97080 Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0191604</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0191604 INIST</idno>
<idno type="RBID">Pascal:04-0191604</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Monoamine oxidase-B inhibition in Alzheimer's disease</title>
<author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name>
<affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1>
<s2>97080 Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Danielczyk, Walter" sort="Danielczyk, Walter" uniqKey="Danielczyk W" first="Walter" last="Danielczyk">Walter Danielczyk</name>
<affiliation><inist:fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grunblatt, Edna" sort="Grunblatt, Edna" uniqKey="Grunblatt E" first="Edna" last="Grünblatt">Edna Grünblatt</name>
<affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1>
<s2>97080 Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurotoxicology : (Park Forest South)</title>
<title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title>
<idno type="ISSN">0161-813X</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurotoxicology : (Park Forest South)</title>
<title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title>
<idno type="ISSN">0161-813X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Inhibition</term>
<term>Inhibitor</term>
<term>Neurology</term>
<term>Toxicology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amine oxidase (flavin-containing)</term>
<term>Inhibition</term>
<term>Inhibiteur</term>
<term>Démence Alzheimer</term>
<term>Neurologie</term>
<term>Toxicologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0161-813X</s0>
</fA01>
<fA03 i2="1"><s0>Neurotoxicology : (Park Forest South)</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Monoamine oxidase-B inhibition in Alzheimer's disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Monoamine Oxidases: Molecular, Pharmacological and Neurotoxicological Aspects. A Tribute to Prof. Merton Sandler</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>RIEDERER (Peter)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DANIELCZYK (Walter)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GRÜNBLATT (Edna)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>NICOTRA (A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>PARVEZ (S. H.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>GLOVER (V.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>SANDLER (M.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="05" i2="1"><s1>PARVEZ (S.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="06" i2="1"><s1>MINAMI (M.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1>
<s2>97080 Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32</s1>
<s2>00198 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS</s1>
<s2>91190 Gif sur Yvette</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road</s1>
<s2>London, W12 ONN</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>The Research Institute of Personalized Health, Health Sciences University of Hokkaido</s1>
<s2>061-0293 Ishikari-Tobetsu</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA15>
<fA20><s1>271-277</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18397</s2>
<s5>354000119285470280</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>2 p.1/2</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0191604</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurotoxicology : (Park Forest South)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B03</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Inhibition</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Inhibition</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inhibición</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Démence Alzheimer</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Neurology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Toxicologie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Toxicology</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Toxicología</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>62</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>63</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>64</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>64</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>64</s5>
</fC07>
<fN21><s1>131</s1>
</fN21>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0191604 INIST</NO>
<ET>Monoamine oxidase-B inhibition in Alzheimer's disease</ET>
<AU>RIEDERER (Peter); DANIELCZYK (Walter); GRÜNBLATT (Edna); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.)</AU>
<AF>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15/97080 Würzburg/Allemagne (1 aut., 3 aut.); Ludwig Boltzmann Institute of Clinical Neurobiology/Vienna/Autriche (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 271-277; Bibl. 2 p.1/2</SO>
<LA>Anglais</LA>
<EA>Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</EA>
<CC>002A25; 002B03; 002B17</CC>
<FD>Amine oxidase (flavin-containing); Inhibition; Inhibiteur; Démence Alzheimer; Neurologie; Toxicologie</FD>
<FG>Oxidoreductases; Enzyme; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie</FG>
<ED>Amine oxidase (flavin-containing); Inhibition; Inhibitor; Alzheimer disease; Neurology; Toxicology</ED>
<EG>Oxidoreductases; Enzyme; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases</EG>
<SD>Amine oxidase (flavin-containing); Inhibición; Inhibidor; Demencia Alzheimer; Neurología; Toxicología</SD>
<LO>INIST-18397.354000119285470280</LO>
<ID>04-0191604</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:04-0191604 |texte= Monoamine oxidase-B inhibition in Alzheimer's disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |